GenMont Biotech Incorporation (3164) Fair Value & Analysis
Healthcare · TW · Market cap 1.4B TWD
Fair value as of: Jul 23, 2026
From 25 valuation models · updated 18 days ago
Share price +0.9% over the past month.
A solid business, but screening 32% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (14.19 TWD). The favourable scenario is already priced in.
- Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 15.90 TWD – 28.12 TWD · fair‑value band 8.48 TWD – 14.19 TWD · the 16.60 TWD price screens above the 11.34 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
GenMont Biotech Incorporation (3164) currently trades at 16.60 TWD, while our model-based Fair Value estimate is 11.34 TWD, implying the stock looks roughly 31.7% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, GenMont Biotech Incorporation generated revenue of 401M TWD at a net margin of 14.3%. Revenue grew 10.7% year over year. It earns a return on equity of 3.3%. Net debt stands at 6.6M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 8.48 TWD (bear case) to 14.19 TWD (bull case); at 16.60 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -32%, 3164 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (12.01 TWD) versus Earnings-Based (5.13 TWD). Highest evidence: Growth DCF (80).
Notify me when 3164 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products.
Full company description
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GenMont Biotech Incorporation reported revenue of 401M TWD in FY2025 versus 428M TWD in FY2021, a compound −1.6%/yr. Reported net income was 57.2M TWD in FY2025, compounding −15.7%/yr from FY2021.
3164 screens 32% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare GenMont Biotech Incorporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GenMont Biotech Incorporation (3164) overvalued or undervalued?
What is the fair value of 3164?
What is the quality score of 3164?
What is the revenue of GenMont Biotech Incorporation (3164)?
What is the net profit margin of 3164?
Does GenMont Biotech Incorporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GenMont Biotech Incorporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.